Hangzhou Valgen Medtech Co., Ltd
12
3
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
DragonFly EU Pivotal Study
Role: lead
DragonFly M2 Pivotal Study
Role: lead
Randomized Controlled Study of Dragonfly System for Functional Mitral Regurgitation
Role: lead
Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation
Role: lead
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
Role: lead
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
Role: lead
Feasibility Study of the DragonFly-T System for Severe Tricuspid Regurgitation
Role: lead
Feasibility Study of Dragonfly System for Severe Tricuspid Regurgitation
Role: lead
Safety and Effectiveness Study of Dragonfly System for Functional Mitral Regurgitation
Role: lead
Dragonfly-M Early Feasibility Study
Role: lead
Safety and Effectiveness Study of Dragonfly System for Degenerative Mitral Regurgitation
Role: lead
Safety and Performance Study of the MitralStitch Repair System.
Role: lead
All 12 trials loaded